✦ LIBER ✦

Zonisamide for essential tremor: An evaluator-blinded study

✍ Scribed by Adrian Handforth; Fredricka C. Martin; Gail A. Kang; Zeba Vanek

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 905 KB
Volume: 24
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22418

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In this evaluator‐blinded open‐treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12‐week extension phase. The primary efficacy outcome variables were blinded rater videotaped/drawing tremor score changes at the Treatment and Extension visits compared to Baseline, based on Fahn‐Tolosa‐Marin and Postural Tremor Scales. Subjects also rated Functional Disabilities. Primary outcomes showed reduced tremor scores at the Treatment (P < 0.00001, n = 25) and Extension (n = 16) visits, at mean doses of 252 and 225 mg/day, respectively. Subject ratings indicated 200 mg/day was superior to 100 mg/day, whereas 300 mg/day produced no additional benefit, but instead was associated with more adverse symptoms, most commonly somnolence, poor energy, imbalance, and altered taste. Future double‐blind placebo‐controlled trials are warranted. © 2008 Movement Disorders Society

📜 SIMILAR VOLUMES

A double-blind placebo-controlled trial

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor

✍ Theresa A. Zesiewicz; Christopher L. Ward; Robert A. Hauser; Juan Sanchez-Ramos; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double‐blind placebo‐controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 6

A double-blind trial of isoniazid for es

A double-blind trial of isoniazid for essential tremor and other action tremors

✍ Dr. Mark Hallett; John Ravits; Richard M. Dubinsky; Marjorie M. Gillespie; Amir 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 1 views

We conducted a double-blind trial of isoniazid in 11 patients with essential tremor and four patients with other types of postural action tremor. The tremor had not been helped by beta-blockers or primidone. Isoniazid was given in doses up to 1,200 mg daily, together with 100 mg pyridoxine, for four

Mirtazapine in essential tremor: A doubl

Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study

✍ Rajesh Pahwa; Kelly E. Lyons 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

## Abstract We sought to determine whether mirtazapine is safe and well‐tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double‐blind, placebo‐controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or

Evaluation of a screening instrument for

Evaluation of a screening instrument for essential tremor

✍ Delia Lorenz; Frank Papengut; Henrik Frederiksen; Florian Kopper; Stephan Klebe; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract To evaluate a screening instrument for essential tremor (ET) consisting of a seven‐item questionnaire and a spiral drawing. A total of 2,448 Danish twins aged 70 years or more and a second sample aged 60 years or more (n = 1,684) from a population‐based northern German cross‐sectional s

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor

✍ Dr. J. Jankovic; K. Schwartz; W. Clemence; A. Aswad; J. Mordaunt 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 585 KB

## Abstract Twenty‐five patients with hand tremor of 2 + (moderate) to 4 + (severe) on the tremor severity rating scale were randomized to receive either 50 U of botulinum toxin (BTX) type A (Allergan, Irvine, CA) or placebo injections into the wrist flexors and extensors of the dominant limb. If p

Tiagabine for essential tremor: An open-

Tiagabine for essential tremor: An open-label trial

✍ Alexandre Gironell; Mercè Martínez-Corral; Xavier Pagonabarraga; Jaime Kulisevsk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 1 views

We agree with Zesiewicz et al.'s findings and emphasize that simply increasing GABAergic stimulation does not necessarily result in tremor improvement in ET. It is clear that more needs to be learnt on the pharmacologic basis of ET.